Endocytic mechanisms controlling functional selectivity of the CB1R
控制 CB1R 功能选择性的内吞机制
基本信息
- 批准号:8745061
- 负责人:
- 金额:$ 31.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnxiety DisordersArrestin Beta 1ArrestinsBar CodesBiochemicalCannabinoidsCannabisCannabis AbuseCannabis-Related DisorderCell membraneCellsClathrinDominant-Negative MutationEndocytosisFamilyFlow CytometryFluorescenceFluorescence MicroscopyFutureG-Protein-Coupled ReceptorsGTP-Binding ProteinsGoalsIndividualKineticsLifeLigandsMAPK8 geneMarijuanaMarijuana DependenceMeasuresMediatingMicroscopyMolecularNeuronsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPhysiologicalPopulationProcessProteinsProto-Oncogene Proteins c-aktPsychotic DisordersRattusReceptor ActivationReceptor SignalingRecruitment ActivityRegulationRoleSignal TransductionSystemTailTechniquesTechnologyTestingTherapeuticTimeTissuesTranslatingWestern BlottingWorkbeta-arrestincannabinoid receptorcellular imagingcoated pitmutantpreventpublic health relevancereceptorresearch study
项目摘要
DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCRs) are one of the largest families of transmembrane receptors and a major target of current therapeutic drugs. At the signaling level, it has become clear that ligands acting on the same receptor can activate multiple and sometime opposing signaling cascades; a process defined as functional selectivity or biased agonism. One of the main effectors of functional selectivity are beta-arrestins, multifunction proteins recruited to activated receptors. However, how receptor activation translates into beta-arrestin signaling is not clearly defined. Our preliminary work combining state-of-the-art live cell imaging with molecular and biochemical techniques identifies ligand-specific dwell times, the time receptors are clustered into individual endocytic pits before endocytosis, as a mechanism by which receptors can control beta-arrestin mediated signaling. Our hypothesis suggests that ligands induce specific phosphorylations at the receptor level, eliciting specific endocytic dwell times during which beta-arrestins remain recruited and engaged in signaling. We propose to define a mechanism by which the Cannabinoid 1 Receptor (CB1R), one of the most abundant receptors in the CNS and target of cannabis, controls beta-arrestin signaling during endocytic dwell times. Our aims are: 1) Characterize ligand-specific dwell times of the CB1R to test our hypothesis that ligands can elicit specific dwell times that ar independent of their endocytic efficacy. 2) Define the mechanisms underlying ligand-specific dwell times of the CB1R. We will test the hypothesis that dwell times are controlled by ligand-specific phosphorylation profiles ("bar-codes") of the receptor. Alternative mechanisms will be also investigated. 3) Determine if beta-arrestin signaling is the physiological target of ligand specific dwell times in heterologous systems and native tissue. Finally, we will test different manipulations to control arrestin signaling by altering CB1R dwell times.
描述(由申请人提供):G蛋白偶联受体(GPCR)是最大的跨膜受体家族之一,也是目前治疗药物的主要靶点。在信号传导水平上,已经清楚的是,作用于同一受体的配体可以激活多个并且有时是相反的信号传导级联;该过程被定义为功能选择性或偏向性激动。功能选择性的主要效应物之一是β-抑制蛋白,一种被激活受体募集的多功能蛋白质。然而,受体激活如何转化为β-抑制蛋白信号转导还没有明确定义。我们的初步工作结合了最先进的活细胞成像与分子和生物化学技术,确定配体特异性停留时间,时间受体聚集成单个内吞凹内吞作用之前,作为受体可以控制β-arrestin介导的信号传导的机制。我们的假设表明,配体在受体水平诱导特异性磷酸化,引发特定的内吞停留时间,在此期间,β-抑制蛋白保持招募和参与信号传导。我们建议定义一种机制,大麻素1受体(CB 1 R)是中枢神经系统中最丰富的受体之一,也是大麻的靶点,它在内吞停留时间内控制β-arrestin信号传导。我们的目标是:1)表征CB 1 R的配体特异性停留时间以测试我们的假设,即配体可以引起不依赖于其内吞功效的特异性停留时间。2)定义CB 1 R的配体特异性停留时间的机制。我们将检验驻留时间受受体的配体特异性磷酸化特征(“条形码”)控制的假设。还将研究替代机制。3)确定β-抑制蛋白信号传导是否是异源系统和天然组织中配体特异性停留时间的生理靶点。最后,我们将测试通过改变CB 1 R停留时间来控制arrestin信号传导的不同操作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guillermo Ariel Yudowski其他文献
Guillermo Ariel Yudowski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guillermo Ariel Yudowski', 18)}}的其他基金
Endocytic mechanisms controlling functional selectivity of the CB1R
控制 CB1R 功能选择性的内吞机制
- 批准号:
8875655 - 财政年份:2014
- 资助金额:
$ 31.5万 - 项目类别:
Endocytic mechanisms controlling functional selectivity of the CB1R
控制 CB1R 功能选择性的内吞机制
- 批准号:
9088437 - 财政年份:2014
- 资助金额:
$ 31.5万 - 项目类别:
Regulation of GPCR Recycling at the Plasma Membrane
质膜上 GPCR 回收的调控
- 批准号:
8231416 - 财政年份:2011
- 资助金额:
$ 31.5万 - 项目类别:
Regulation of GPCR Recycling at the Plasma Membrane
质膜上 GPCR 回收的调控
- 批准号:
8134110 - 财政年份:2011
- 资助金额:
$ 31.5万 - 项目类别:
Regulation of GPCR Recycling at the Plasma Membrane
质膜上 GPCR 回收的调控
- 批准号:
8432875 - 财政年份:2011
- 资助金额:
$ 31.5万 - 项目类别:
Regulation of GPCR Recycling at the Plasma Membrane
质膜上 GPCR 回收的调控
- 批准号:
7294762 - 财政年份:2007
- 资助金额:
$ 31.5万 - 项目类别:
Regulation of GPCR Recycling at the Plasma Membrane
质膜上 GPCR 回收的调控
- 批准号:
7456554 - 财政年份:2007
- 资助金额:
$ 31.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 31.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)